The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 105.50
Bid: 103.00
Ask: 108.00
Change: -0.50 (-0.47%)
Spread: 5.00 (4.854%)
Open: 105.50
High: 105.00
Low: 105.00
Prev. Close: 105.50
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US Expansion

12 Dec 2011 07:00

RNS Number : 7450T
Intercede Group PLC
12 December 2011
 



 

 

Intercede Group plc

 

Intercede Continues US Expansion

 

Company Secures E2 Treaty Investor Status

 

 

Leicestershire, England, December 12, 2011 - Intercede Group plc, the developer of the Intercede MyID® Identity and Credential Management System today announces its has been approved as a United States Treaty Investor (E2) by the US Embassy in London.

 

The company is now able to send qualified executives and employees who are UK citizens to work for Intercede MyID Inc., subject only to them meeting the requirements appropriate to E2 status. Intercede MyID Inc is a wholly owned subsidiary of the Intercede Group with offices in Reston, VA.

 

Treaty Investor employees qualify for E-2 work visas. These are non-immigrant visas for nationals of a country with which the United States maintains a treaty of friendship, commerce and navigation who wish to go to the United States to develop and direct the operations of an enterprise in which the Treaty Investor is investing a substantial amount of capital.

 

Richard Parris, Intercede Chairman and Chief Executive said; "I am delighted Intercede has been recognized as an E2 Treaty Investor. This is the result of an extensive application process. We now have the flexibility to more easily outpost key UK staff to our US business in order to accelerate its growth. This will enable Intercede to strengthen its US infrastructure, transfer technology, recruit and train more US staff, extend the Intercede corporate culture to a wider team and provide US opportunities and experiences to our UK staff. I believe this is a key milestone in the corporate development of the Intercede Group and will be instrumental in enabling increased revenues to be generated from the North American market."

 

 

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

 

Andrew Walker, Finance Director

 

 

 

FinnCap

Tel. +44 (0)20 7600 1658

Charles Cunningham, Corporate Finance

 

Rose Herbert, Corporate Finance

 

Joanna Weaving, Corporate Broking

 

 

Pelham Bell Pottinger

Tel. +44 (0)20 7861 3112

Archie Berens

 

Clare Gilbey

 

 

 

 

 

 

 

About Intercede:

Intercede is the producer of the MyID Identity and Credential Management System and MyID Management Agent for Microsoft Forefront Identity Manager 2010.

 

Intercede MyID technology is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 14 federal agencies, two million smart cards in support of the US Transportation Worker Identity Credential program (TWIC), four US financial institutions and 340,000 smart corporate identity badges for Boeing, Booz Allen Hamilton and Lockheed Martin. In Europe, Australasia and the Middle East, Intercede MyID is being deployed in support of government identity, financial services, health and corporate employee ID security projects.

 

Intercede MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and management.

 

Intercede MyID was the first electronic personalization product to achieve compliance with the US FIPS-201 Personal Identity Verification (PIV) standard and is widely deployed by federal agencies, government contractors and other commercial entities. In particular, it supports the latest standards applicable for all PIV, PIV-Interoperable and PIV-Compatible deployments.

 

It can issue and manage a wide variety of identities and credentials, providing customers with a platform that can meet their needs now and in the future. It is a fully supported commercial off-the-shelf product that can be quickly deployed for thousands or millions of users.

 

For more information contact:

info@intercede.com or visit www.intercede.com or call +44-1455-558111

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUAAARASAUAUA
Date   Source Headline
26th Apr 202410:02 amRNSShare Incentive Scheme
23rd Apr 20247:00 amRNSCapital Markets Day
8th Apr 20247:00 amRNSTrading Update
2nd Apr 20247:00 amRNSContract and Subscription Renewals
25th Mar 20243:38 pmRNSHolding(s) in Company
25th Mar 20243:35 pmRNSHolding(s) in Company
22nd Mar 20247:00 amRNSNew Orders and Trading Update
21st Mar 20247:00 amRNSNew Product Announcement: Launch of MyID MFA v5
6th Feb 20247:00 amRNSDirector/PDMR Shareholding
29th Jan 20247:00 amRNSNew Orders
18th Jan 20249:55 amRNSDirector/PDMR Shareholding
3rd Jan 20247:00 amRNSMajor New Contract Win
7th Dec 20237:00 amRNSUpdate on Major New Contract Win
5th Dec 202312:30 pmRNSMajor New Contract with Large US Federal Agency
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
21st Nov 20237:01 amRNSNew Contract and Renewal Orders
21st Nov 20237:00 amRNSHalf-year Report
7th Nov 20237:00 amRNSContract and Renewals Orders
25th Oct 20234:44 pmRNSDirector/PDMR Shareholding
24th Oct 20237:00 amRNSNotice of Interim Results & Investor Presentation
20th Oct 20237:03 amRNSAppointment of Non-Executive Director
11th Oct 20237:00 amRNSDirector/PDMR Shareholding
10th Oct 20237:00 amRNSTrading Update
21st Sep 20231:31 pmRNSResult of AGM
4th Sep 20237:00 amRNSContract and Renewals Orders
30th Aug 20237:10 amRNSNotice of AGM and Publication of Annual Report
20th Jun 20237:01 amRNSBoard Changes
20th Jun 20237:00 amRNSFinal Results
12th Jun 20237:00 amRNSNotice of Results & Investor Presentation
27th Apr 20237:00 amRNSShare Incentive Plan
17th Apr 20237:00 amRNSTrading Update
3rd Apr 20237:00 amRNSContract wins/renewals
3rd Feb 202310:46 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSChange of Auditors
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
23rd Jan 20232:00 pmRNSPrice Monitoring Extension
23rd Jan 20237:00 amRNSTrading Update
11th Jan 20232:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20228:45 amRNSDirector/PDMR Shareholding
22nd Nov 20227:00 amRNSHalf-year Report
11th Nov 20227:00 amRNSNotice of Interim Results & Investor Presentation
13th Oct 202210:30 amRNSDirector/PDMR Shareholding
11th Oct 20221:00 pmRNSDirector/PDMR Shareholding
10th Oct 20228:00 amRNSLong Term Incentive Plan
10th Oct 20227:01 amRNSAcquisition of Authlogics Ltd
10th Oct 20227:00 amRNSTrading Update
28th Sep 202212:22 pmRNSResult of AGM
15th Sep 20227:00 amRNSDirector/PDMR Shareholding and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.